Published in Curr Opin HIV AIDS on March 01, 2006
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol (2006) 1.35
Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math Biosci (2008) 1.05
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Kinetics of influenza A virus infection in humans. J Virol (2006) 3.78
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Acute loss of intestinal CD4+ T cells is not predictive of simian immunodeficiency virus virulence. J Immunol (2007) 3.24
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A (2014) 2.95
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci U S A (2013) 2.79
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature (2004) 2.74
Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology (2003) 2.50
Modeling sequence evolution in acute HIV-1 infection. J Theor Biol (2009) 2.32
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
The complexity of complexes in signal transduction. Biotechnol Bioeng (2003) 2.20
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. J Acquir Immune Defic Syndr (2004) 2.05
Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection. J Immunol (2003) 2.03
Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol (2010) 2.02
Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl (2006) 2.01
Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology (2007) 2.00
CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog (2010) 1.99
Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis (2003) 1.90
Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy. J Theor Biol (2007) 1.89
Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS (2011) 1.88
Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration. Hepatology (2011) 1.87
Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol (2003) 1.87
In vivo dynamics of T cell activation, proliferation, and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci U S A (2002) 1.82
Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol (2010) 1.80
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol (2009) 1.78
Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection. J Virol (2004) 1.77
Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol (2009) 1.76
Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol (2007) 1.74
ON IDENTIFIABILITY OF NONLINEAR ODE MODELS AND APPLICATIONS IN VIRAL DYNAMICS. SIAM Rev Soc Ind Appl Math (2011) 1.69
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology (2006) 1.69
Polyspecificity of T cell and B cell receptor recognition. Semin Immunol (2007) 1.68
Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut (2013) 1.63
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61
Impact of thymectomy on the peripheral T cell pool in rhesus macaques before and after infection with simian immunodeficiency virus. Eur J Immunol (2005) 1.60
Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. J Virol (2011) 1.57
Parameter identifiability and estimation of HIV/AIDS dynamic models. Bull Math Biol (2008) 1.56
Drug resistance and influenza pandemics. Lancet (2002) 1.55
Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.54
Estimating lymphocyte division and death rates from CFSE data. Bull Math Biol (2006) 1.53
Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance. J Acquir Immune Defic Syndr (2005) 1.52
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. J Virol (2008) 1.51
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Modeling amantadine treatment of influenza A virus in vitro. J Theor Biol (2008) 1.51
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Simian immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol (2008) 1.49
Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A (2007) 1.48
Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. Gastroenterology (2005) 1.47
HIV-1 infection and low steady state viral loads. Bull Math Biol (2002) 1.46
Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis (2002) 1.45
Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics (2010) 1.45
Agent-based modeling of host-pathogen systems: The successes and challenges. Inf Sci (Ny) (2009) 1.43
Multiplicity of human immunodeficiency virus infections in lymphoid tissue. J Virol (2004) 1.43
Complete genetic linkage can subvert natural selection. Proc Natl Acad Sci U S A (2007) 1.42
Mathematical analysis of delay differential equation models of HIV-1 infection. Math Biosci (2002) 1.41
Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol (2006) 1.41
Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLoS Comput Biol (2008) 1.39
Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. J Theor Biol (2004) 1.39
HIV dynamics with multiple infections of target cells. Proc Natl Acad Sci U S A (2005) 1.36
Acute hepatitis A virus infection is associated with a limited type I interferon response and persistence of intrahepatic viral RNA. Proc Natl Acad Sci U S A (2011) 1.36
Quantifying T lymphocyte turnover. J Theor Biol (2013) 1.35
Viral and latent reservoir persistence in HIV-1-infected patients on therapy. PLoS Comput Biol (2006) 1.35
Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol (2006) 1.31
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog (2012) 1.30
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals. AIDS (2003) 1.30
Early hepatitis C viral kinetics correlate with long-term outcome in patients receiving high dose induction followed by combination interferon and ribavirin therapy. J Hepatol (2002) 1.30
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol (2011) 1.28
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis (2003) 1.27
Modeling within-host dynamics of influenza virus infection including immune responses. PLoS Comput Biol (2012) 1.26
Characterizing T cell movement within lymph nodes in the absence of antigen. J Immunol (2007) 1.24
Modeling subgenomic hepatitis C virus RNA kinetics during treatment with alpha interferon. J Virol (2009) 1.23
Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. Gastroenterology (2013) 1.23
Influence of peak viral load on the extent of CD4+ T-cell depletion in simian HIV infection. J Acquir Immune Defic Syndr (2006) 1.23
Estimates of intracellular delay and average drug efficacy from viral load data of HIV-infected individuals under antiretroviral therapy. Antivir Ther (2004) 1.23
Determining thymic output quantitatively: using models to interpret experimental T-cell receptor excision circle (TREC) data. Immunol Rev (2007) 1.23
Modeling HCV kinetics under therapy using PK and PD information. Expert Opin Drug Metab Toxicol (2009) 1.22
Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells. J Virol (2006) 1.21
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J Antimicrob Chemother (2008) 1.21
How antigen quantity and quality determine T-cell decisions in lymphoid tissue. Mol Cell Biol (2008) 1.20
Dynamics of hepatitis B virus infection. Microbes Infect (2002) 1.20
A stochastic model of cytotoxic T cell responses. J Theor Biol (2004) 1.20
The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc Natl Acad Sci U S A (2007) 1.19
Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med (2010) 1.18
Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology (2002) 1.18
Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis (2003) 1.18
Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments. Bull Math Biol (2008) 1.17
Kinetics of coinfection with influenza A virus and Streptococcus pneumoniae. PLoS Pathog (2013) 1.16
Stochastic theory of early viral infection: continuous versus burst production of virions. PLoS Comput Biol (2011) 1.15
Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues. PLoS Comput Biol (2010) 1.15
Dynamics of T- and B-lymphocyte turnover in a natural host of simian immunodeficiency virus. J Virol (2007) 1.15
Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci (2004) 1.14